Times Medicament Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Times Medicament Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $929.3K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Times Medicament Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $929.3K Trade | TransData Nexus

Times Medicament Private Limited

Indian Pharmaceutical Exporter · Diabetes & Endocrine Specialist · $929.3K Total Trade · DGFT Verified

Times Medicament Private Limited is an Indian pharmaceutical exporter with a total trade value of $929.3K across 2 products in 2 therapeutic categories. Based on 23 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Insulin ($913.8K), Ustekinumab ($15.6K), .

Times Medicament Private Limited — Export Portfolio & Destination Treemap

Times Medicament Private Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Times Medicament Private Limited? — Company Overview & Market Position

Times Medicament Private Limited is a pharmaceutical company based in Ahmedabad, Gujarat, India, established on June 10, 2020. The company is registered under the Corporate Identification Number (CIN) U85110GJ2020PTC113895. It operates as a private limited company with an authorized and paid-up capital of ₹100,000. The registered office is located at 913, One World West, Vejalpur, Ahmedabad City, Gujarat, 380051, India.

The company's primary focus is on the development and distribution of high-quality pharmaceutical formulations, including tablets, capsules, syrups, and injections. Times Medicament Private Limited is committed to enhancing global healthcare by providing accessible and affordable medications.

What Does Times Medicament Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Insulin$913.8K 2Ustekinumab$15.6K

Product Portfolio — Top 2 by Export Value

Times Medicament Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Insulin	Diabetes & Endocrine	$913.8K	20	1.2%	9
2	Ustekinumab	Biologics & Immunotherapy	$15.6K	3	1.2%	12

Times Medicament Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $929.3K. The top category is Diabetes & Endocrine (98.3% of portfolio), followed by Biologics & Immunotherapy (1.7%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Times Medicament Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Specific details regarding the manufacturing facilities of Times Medicament Private Limited are not publicly disclosed. The company is known to engage in the wholesale and export of pharmaceutical products, including tablets, capsules, and injections. However, comprehensive information about plant locations, capacities, and specializations is not available in the provided sources.

3Key Leadership

As of the latest available information, the key leadership of Times Medicament Private Limited includes:

Sumeet Babulal Goyani: Director since June 10, 2020.

Bipinkumar Babubhai Mer: Appointed as Director on March 16, 2024.

The company's leadership is committed to upholding values of integrity, transparency, and customer satisfaction, guiding every aspect of its operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Times Medicament Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Times Medicament Private Limited's export data indicates a focus on the Diabetes & Endocrine therapeutic category, with insulin products accounting for 98.3% of exports. The company has engaged in 23 shipments totaling $929,000 USD, with insulin contributing $914,000 USD and ustekinumab $16,000 USD. However, specific details regarding regulatory filings, approvals, and market access status in the US, EU, UK, Australia, and Japan are not publicly available. The company's export activities primarily target markets where insulin is in demand, but comprehensive regulatory information is lacking.

2Emerging Markets

Times Medicament Private Limited's export data does not provide specific insights into its presence in emerging markets such as Africa, Latin America, and Southeast Asia. The company's focus on insulin suggests potential engagement in regions with high diabetes prevalence. However, without explicit data on WHO prequalification or other certifications, it is challenging to assess the company's penetration in these markets.

3Geographic Strategy

The company's export portfolio is heavily concentrated, with insulin accounting for 98.3% of exports. This concentration indicates a strategic focus on a single product category, which may expose the company to risks associated with market fluctuations and regulatory changes affecting insulin. Diversifying the product portfolio and exploring new geographic markets could mitigate these risks and enhance the company's strategic position.

Times Medicament Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding Times Medicament Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company's export data does not indicate a significant presence in the US market, suggesting limited or no FDA approvals. Without detailed regulatory filings, it is difficult to assess the company's standing with the FDA.

2WHO & EU GMP

There is no publicly available information confirming whether Times Medicament Private Limited holds WHO prequalification or EU Good Manufacturing Practice (GMP) certificates. The company's export data does not provide insights into its compliance with these international standards. Without such certifications, the company's ability to access certain global markets may be limited.

3CDSCO & Indian Regulatory

Times Medicament Private Limited is registered with the Central Drugs Standard Control Organisation (CDSCO) under the CIN U85110GJ2020PTC113895. Specific details regarding CDSCO manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly disclosed. The company's export data indicates a focus on insulin products, but without explicit regulatory information, it is challenging to assess compliance with Indian regulatory requirements.

Times Medicament Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the insulin market, Times Medicament Private Limited faces competition from both domestic and international pharmaceutical companies. While specific market share data is not available, the company's export data indicates a focus on insulin products, suggesting a competitive positioning in this therapeutic category. A more detailed analysis would require access to comprehensive market reports and competitor data.

2Key Differentiators

Times Medicament Private Limited's key differentiator lies in its specialized focus on insulin products, catering to the global demand for diabetes management. The company's commitment to high-quality formulations and customer satisfaction underscores its competitive advantage. However, the lack of a diversified product portfolio may limit its ability to adapt to changing market dynamics.

3Strategic Position

Currently, Times Medicament Private Limited's strategic direction appears to be centered on the production and export of insulin products. The company's heavy reliance on a single product category suggests a need for diversification to enhance resilience and growth prospects. Exploring opportunities in generics, specialty drugs, biosimilars, or Contract Development and Manufacturing Organizations (CDMO) could provide avenues for future expansion.

Buyer Due Diligence Brief — Evaluating Times Medicament Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Times Medicament Private Limited's export data indicates a consistent volume of shipments, primarily focused on insulin products. The company's commitment to high-quality formulations and customer satisfaction suggests reliability as a supplier. However, the lack of detailed information on manufacturing facilities and regulatory compliance makes it challenging to fully assess the company's track record and consistency.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm the company's FDA facility registrations and approved ANDAs.

WHO-GMP Certification: Verify compliance with World Health Organization Good Manufacturing Practice standards.

EU GMP Certification: Ensure adherence to European Union Good Manufacturing Practice standards.

Frequently Asked Questions — Times Medicament Private Limited

How many pharmaceutical products does Times Medicament Private Limited export from India?

Times Medicament Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Insulin ($913.8K), Ustekinumab ($15.6K). Total export value is $929.3K.

What is Times Medicament Private Limited's total pharmaceutical export value?

Times Medicament Private Limited's total pharmaceutical export value is $929.3K, based on 23 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Times Medicament Private Limited cover?

Times Medicament Private Limited exports across 2 therapeutic categories. The largest are Diabetes & Endocrine (98.3%, 1 products), Biologics & Immunotherapy (1.7%, 1 products).

Get Full Times Medicament Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.